Analysis of Ramucirumab Suggests Risks Outweigh Benefits
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
Gastric Cancer
Antibody-Drug Conjugate for Advanced HER2-Positive Gastric Cancer Improves Outcomes
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
3 Years of Adjuvant Imatinib Improves Long-Term Overall Survival in Gastrointestinal Stromal Tumor
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
Weight Loss Following Chemotherapy Was Associated With Worse Outcomes in Patients With Advanced Gastric Cancer
These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.
Biosimilar Ontruzant Now Available for Breast Cancer, Gastric Cancer Treatment
Ontruzant is supplied in 150 mg single-dose vials and 420 mg multidose vials.
Enhanced Recovery After Surgery Approach Evaluated as Postoperative Care for Early-Stage Gastric Cancer
ERAS clinical pathways typically involve early ambulation, and the early introduction of liquid and solid diets following surgery.
Avelumab Maintenance: No OS Benefit vs Continued Chemotherapy in HER2-Negative Gastrointestinal Cancers
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Use of Value Pathways to Guide Treatment Decisions in Gastric Cancer Had Little Impact on Overall Survival
Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.
Progression-Free Rate With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Associated With PD-L1 Level
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
-
Loading...
-
Loading...
Next post in ASCO GI 2020
